ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
Primary Purpose
Post-ERCP Acute Pancreatitis
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
EST+LBD+ENBD
EST+LBD
Sponsored by
About this trial
This is an interventional prevention trial for Post-ERCP Acute Pancreatitis
Eligibility Criteria
Inclusion Criteria:
- Patients with visualized bile duct stones ≥12 mm in maximum transverse diameter. - Males and females, age > 18 years.
- Normal amylase level before undergoing ERCP.
- Signed inform consent form and agreed to follow-up on time.
Exclusion Criteria:
- Bleeding diathesis
- Prior EST or EPBD or ENBD
- Billroth II or Roux-en-Y anatomy
- Distal extrahepatic bile duct stenosis
- Acute pancreatitis
- Intrahepatic bile duct stones.
Sites / Locations
- Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
EST+LBD+ENBD group
EST+LBD group
Arm Description
Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Outcomes
Primary Outcome Measures
The prophylaxis effect of ENBD on post-ERCP pancreatitis after endoscopic sphincterotomy plus LBD for the treatment of large bile duct stones.
If the serum amylase of patients elevation and 3 times higher than the normal values after ERCP 24 hours in high risk patients, who also have clinical symptoms, without other acute abdominal diseases,such as gastrointestinal perforation,acute cholecystitia and acute cholangitis and etc. In this condition, it will be defined PEP(post-ERCP pancreatitis).
Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.
Secondary Outcome Measures
Compare EST+LBD+ENBD group EST+LBD with group on the incidence of hyperamylasemia/adverse events.
Hyperamylasemia will be defined as the serum amylase 3 times more than the upper normal values, without clinical symptoms. During the study, any unexpected medical issue will be called adverse event.
Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02830984
Brief Title
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
Official Title
Nasobiliary Drainage After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing Postoperative Pancreatitis in Treating of Large Bile Duct Stones
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
July 2017 (Anticipated)
Study Completion Date
July 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Anhui Provincial Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Endoscopic retrograde cholangiopancreatography (ERCP) has become one of the most important techniques in the treatment of bile duct stones. A number of studies have been conducted using large-balloon dilation (LBD) after adequate EST to extract large bile duct stones. In those studies, the authors suggested that EST plus LBD might lower the risk of post procedure pancreatitis (PEP) by directing balloon dilation toward the bile duct rather than the pancreatic duct. It has been reported that EPBD followed by insertion of nasobiliary drainage catheter can prevent PEP. However, it is still unclear that nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation for preventing postoperative pancreatitis in treating of large bile duct stones.The investigators therefore designed a prospective randomized trial to determine whether nasobiliary drainage prevent PEP after endoscopic sphincterotomy plus LBD for the treatment of large bile duct stones.
Detailed Description
Patients enrolled were confirmed the presence of CBD stones using magnetic resonance cholangiopancreatography. Patients with large bile duct stones were randomly assigned to EST+LBD+ENBD group and EST+LBD group. A descriptive analysis will be performed on primary endpoint, containing frequency of number and percentage of patients. A two proportion equality test will be conducted to explore whether incidence rates are different. Descriptive statistics including number (N), mean, median, standard deviation, minimum and maximum, will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-ERCP Acute Pancreatitis
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
EST+LBD+ENBD group
Arm Type
Experimental
Arm Description
Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Arm Title
EST+LBD group
Arm Type
Active Comparator
Arm Description
Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Intervention Type
Procedure
Intervention Name(s)
EST+LBD+ENBD
Intervention Description
Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Intervention Type
Procedure
Intervention Name(s)
EST+LBD
Intervention Description
Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
Primary Outcome Measure Information:
Title
The prophylaxis effect of ENBD on post-ERCP pancreatitis after endoscopic sphincterotomy plus LBD for the treatment of large bile duct stones.
Description
If the serum amylase of patients elevation and 3 times higher than the normal values after ERCP 24 hours in high risk patients, who also have clinical symptoms, without other acute abdominal diseases,such as gastrointestinal perforation,acute cholecystitia and acute cholangitis and etc. In this condition, it will be defined PEP(post-ERCP pancreatitis).
Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.
Time Frame
the incidence of post-ERCP pancreatitis at 24 h after ERCP in two groups
Secondary Outcome Measure Information:
Title
Compare EST+LBD+ENBD group EST+LBD with group on the incidence of hyperamylasemia/adverse events.
Description
Hyperamylasemia will be defined as the serum amylase 3 times more than the upper normal values, without clinical symptoms. During the study, any unexpected medical issue will be called adverse event.
Descriptive statistics will be produced for all continuous variables. Frequency tables of number (N) and percentage of subjects will be produced for all categorical variables.
Time Frame
the incidence of hyperamylasemia/adverse events at 24 h after ERCP in two groups
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with visualized bile duct stones ≥12 mm in maximum transverse diameter. - Males and females, age > 18 years.
Normal amylase level before undergoing ERCP.
Signed inform consent form and agreed to follow-up on time.
Exclusion Criteria:
Bleeding diathesis
Prior EST or EPBD or ENBD
Billroth II or Roux-en-Y anatomy
Distal extrahepatic bile duct stenosis
Acute pancreatitis
Intrahepatic bile duct stones.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shao Feng, MD
Phone
8613033090788
Email
tagsmile1985@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shao Feng, MD
Organizational Affiliation
Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University
City
HeFei
State/Province
Anhui
ZIP/Postal Code
230001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shao Feng, MD
Phone
8613033090788
Email
tagsmile1985@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
We'll reach out to this number within 24 hrs